Filings

9 documents · 44 matches

1. VVOS Vivos Therapeutics, Inc. 10-K 2026-04-15

   Item 8. Financial Statements and Supplementary Data.

   going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations
   10 matches in this document Show context Copy citation

2. VVOS Vivos Therapeutics, Inc. 8-K 2026-10-01

   Item 4.01. Changes in Registrant’s Certifying Accountant.

   both such reports included explanatory paragraphs expressing substantial doubt regarding the Company’s ability to continue as a going concern.
   1 match in this document Show context Copy citation

3. VVOS Vivos Therapeutics, Inc. 10-Q 2026-08-14

   Item 6. Exhibits, Financial Statement Schedules 40

   ● our ability to generate cash flow and profitability and continue as a going concern;
   6 matches in this document Show context Copy citation

4. VVOS Vivos Therapeutics, Inc. 10-Q 2026-05-20

   Item 6. Exhibits, Financial Statement Schedules 46

   ● our ability to generate cash flow and profitability and continue as a going concern;
   6 matches in this document Show context Copy citation

5. VVOS Vivos Therapeutics, Inc. 10-Q 2025-11-19

   Item 6. Exhibits, Financial Statement Schedules 49

   ● our ability to generate cash flow and profitability and continue as a going concern;
   6 matches in this document Show context Copy citation

6. VVOS Vivos Therapeutics, Inc. 8-K/A 2025-08-25

   continue as a going concern within one year after the date that the financial statements are available to be issued.
   2 matches in this document Show context Copy citation

7. VVOS Vivos Therapeutics, Inc. 10-Q 2025-08-19

   Item 6. Exhibits, Financial Statement Schedules 45

   ● our ability to generate cash flow and profitability and continue as a going concern;
   6 matches in this document Show context Copy citation

8. VVOS Vivos Therapeutics, Inc. 8-K 2025-06-06

   Item 4.01. Changes in Registrant’s Certifying Accountant

   December 31, 2024, Moss Adams’ audit report on the consolidated financial statements contained an explanatory paragraph regarding a going concern uncertainty.
   1 match in this document Show context Copy citation

9. VVOS Vivos Therapeutics, Inc. 10-Q 2025-05-15

   Item 6. Exhibits, Financial Statement Schedules 36

   ● our ability to generate cash flow and profitability and continue as a going concern;
   6 matches in this document Show context Copy citation